OOIR: Observatory of International Research

Papers

(The median citation count of Neurology-Neuroimmunology & Neuroinflammation is 7. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes	374
Peripheral Neuropathy Evaluations of Patients With Prolonged Long COVID	120
Anti–SARS-CoV-2 antibodies in the CSF, blood-brain barrier dysfunction, and neurological outcome	109
Neurosarcoidosis	106
Acute Disseminated Encephalomyelitis and Acute Hemorrhagic Leukoencephalitis Following COVID-19	90
International Consensus Recommendations for the Treatment of Pediatric NMDAR Antibody Encephalitis	88
Epidemiology of paraneoplastic neurologic syndromes and autoimmune encephalitides in France	85
Rituximab Treatment and Long-term Outcome of Patients With Autoimmune Encephalitis	84
Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgG–Associated Disease and Neuromyelitis Optica Spectrum Disorders	79
Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19	74
COVID-19 Among Patients With Multiple Sclerosis	72
Serum GFAP and NfL Levels Differentiate Subsequent Progression and Disease Activity in Patients With Progressive Multiple Sclerosis	68
Overlapping central and peripheral nervous system syndromes in MOG antibody–associated disorders	68
Slowly Expanding Lesions Predict 9-Year Multiple Sclerosis Disease Progression	61
Dysregulation of the Adaptive Immune System in Patients With Early-Stage Parkinson Disease	60
Presentations and mechanisms of CNS disorders related to COVID-19	57
IgG4-Mediated Neurologic Autoimmunities	56
COVID-19 Severity in Multiple Sclerosis	56
New BBB Model Reveals That IL-6 Blockade Suppressed the BBB Disorder, Preventing Onset of NMOSD	54
Clinical and Prognostic Value of Immunogenetic Characteristics in Anti-LGI1 Encephalitis	53
Retinal Optical Coherence Tomography in Neuromyelitis Optica	53
Myelin Oligodendrocyte Glycoprotein-Immunoglobulin G in the CSF	53
Plasma Markers of Neurologic Injury and Inflammation in People With Self-Reported Neurologic Postacute Sequelae of SARS-CoV-2 Infection	49
Pain, Depression, and Quality of Life in Neuromyelitis Optica Spectrum Disorder	47
Chitinases and chitinase-like proteins as biomarkers in neurologic disorders	46

Anti-CD20 therapies and pregnancy in neuroimmunologic disorders	46
Immune profiling of plasma-derived extracellular vesicles identifies Parkinson disease	45
Choroid Plexus Volume in Multiple Sclerosis vs Neuromyelitis Optica Spectrum Disorder	45
Hypogammaglobulinemia and Infections in Patients With Multiple Sclerosis Treated With Rituximab	45
Anti-IgLON5 Disease	44
Long-term Functional Outcomes and Relapse of Anti-NMDA Receptor Encephalitis	44
Effect of Ocrelizumab in Blood Leukocytes of Patients With Primary Progressive MS	43
Toward Precision Phenotyping of Multiple Sclerosis	41
Efficacy and Safety of Masitinib in Progressive Forms of Multiple Sclerosis	41
Leveraging Visual Outcome Measures to Advance Therapy Development in Neuroimmunologic Disorders	40
Plasma Biomarkers of Neuropathogenesis in Hospitalized Patients With COVID-19 and Those With Postacute Sequelae of SARS-CoV-2 Infection	39
Discontinuation of Immunosuppressive Therapy in Patients With Neuromyelitis Optica Spectrum Disorder With Aquaporin-4 Antibodies	39
Seizure-related 6 homolog like 2 autoimmunity	39
Gene-Environment Interactions in Multiple Sclerosis	38
Diagnosis and Management of Opsoclonus-Myoclonus-Ataxia Syndrome in Children	38
Population-Based Epidemiology Study of Paraneoplastic Neurologic Syndromes	38
Targeting B Cells to Modify MS, NMOSD, and MOGAD	36
Encephalopathies Associated With Severe COVID-19 Present Neurovascular Unit Alterations Without Evidence for Strong Neuroinflammation	35
Longitudinally Extensive Myelitis Associated With Immune Checkpoint Inhibitors	35
Cladribine vs other drugs in MS	35
Microglia Activation in Basal Ganglia Is a Late Event in Huntington Disease Pathophysiology	34
Impact of Disease-Modifying Treatments of Multiple Sclerosis on Anti–SARS-CoV-2 Antibodies	34
Microglia as Central Protagonists in the Chronic Stress Response	34
Abnormal B-Cell and Tfh-Cell Profiles in Patients With Parkinson Disease	34
Prognostic Accuracy of NEDA-3 in Long-term Outcomes of Multiple Sclerosis	34
Amyotrophic Lateral Sclerosis Survival Associates With Neutrophils in a Sex-specific Manner	33
Exercise Diminishes Plasma Neurofilament Light Chain and Reroutes the Kynurenine Pathway in Multiple Sclerosis	33
Increased Serum Neurofilament Light and Thin Ganglion Cell–Inner Plexiform Layer Are Additive Risk Factors for Disease Activity in Early Multiple Sclerosis	33
Thymoma and Autoimmune Encephalitis	33
Updated Results of the COVID-19 in MS Global Data Sharing Initiative	32
Dimethyl Fumarate Reduces Inflammation in Chronic Active Multiple Sclerosis Lesions	32
Kappa-Free Light Chains in CSF Predict Early Multiple Sclerosis Disease Activity	32
CSF Findings in Acute NMDAR and LGI1 Antibody–Associated Autoimmune Encephalitis	32
Progranulin Suppressed Autoimmune Uveitis and Autoimmune Neuroinflammation by Inhibiting Th1/Th17 Cells and Promoting Treg Cells and M2 Macrophages	31
Clinical and Laboratory Features in Anti-NF155 Autoimmune Nodopathy	31
Heterogeneity of Acetylcholine Receptor Autoantibody–Mediated Complement Activity in Patients With Myasthenia Gravis	31
Temporal Dynamics of MOG Antibodies in Children With Acquired Demyelinating Syndrome	31
Potential Role of CHI3L1+ Astrocytes in Progression in MS	30
Imaging Characteristics of Choroid Plexuses in Presymptomatic Multiple Sclerosis	30
Anti-Hu Antibodies in Patients With Neurologic Side Effects of Immune Checkpoint Inhibitors	30
High serum neurofilament associates with diffuse white matter damage in MS	30
Systemic Inflammation Is Associated With Neurologic Involvement in Pediatric Inflammatory Multisystem Syndrome Associated With SARS-CoV-2	30
Risk of Getting COVID-19 in People With Multiple Sclerosis	30
Incidence and Impact of COVID-19 in MS	30
Early Immunotherapy and Longer Corticosteroid Treatment Are Associated With Lower Risk of Relapsing Disease Course in Pediatric MOGAD	30
Aryl Hydrocarbon Receptor Activation in Astrocytes by Laquinimod Ameliorates Autoimmune Inflammation in the CNS	30
Evaluation of Age-Dependent Immune Signatures in Patients With Multiple Sclerosis	29
Anti-NMDAR Encephalitis in the Netherlands, Focusing on Late-Onset Patients and Antibody Test Accuracy	29
Clostridium bolteae is elevated in neuromyelitis optica spectrum disorder in India and shares sequence similarity with AQP4	29
Primary Angiitis of the CNS	29

Serum neurofilament light chain	29
Rituximab-Induced Hypogammaglobulinemia and Infections in AQP4 and MOG Antibody–Associated Diseases	28
Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder	28
Role of Chitinase 3–like 1 as a Biomarker in Multiple Sclerosis	28
COVID-19 Vaccination Reactogenicity in Persons With Multiple Sclerosis	28
Effects of Vitamin D and Body Mass Index on Disease Risk and Relapse Hazard in Multiple Sclerosis	27
Cortical Thickness and Serum NfL Explain Cognitive Dysfunction in Newly Diagnosed Patients With Multiple Sclerosis	27
Neuroprotective Properties of 4-Aminopyridine	27
Human Herpesvirus 6 Encephalitis in Immunocompetent and Immunocompromised Hosts	27
Acute Inflammatory Diseases of the Central Nervous System After SARS-CoV-2 Vaccination	27
Clinical and Radiologic Disease Activity in Pregnancy and Postpartum in MS	26
Vaccine Hesitancy in Patients With Multiple Sclerosis	26
SARS-CoV-2 Infection in Multiple Sclerosis	26
MRI Characteristics of Autoimmune Encephalitis With Autoantibodies to GABAA Receptor	26
Interleukin-26, preferentially produced by T _H 17 lymphocytes, regulates CNS barrier function	26
Secondary Progressive Multiple Sclerosis	26
Targeting B cells to modify MS, NMOSD, and MOGAD	26
Recovery From COVID-19 in Multiple Sclerosis	25
Increased Remyelination and Proregenerative Microglia Under Siponimod Therapy in Mechanistic Models	24
Autoimmune Encephalitis Resembling Dementia Syndromes	24
Sustained Low Relapse Rate With Highly Variable B-Cell Repopulation Dynamics With Extended Rituximab Dosing Intervals in Multiple Sclerosis	24
Mesenchymal stem cell-derived neural progenitors in progressive MS	24
COVID-19 Infection in Fingolimod- or Siponimod-Treated Patients	24
Combined Regulatory T-Lymphocyte and IL-2 Treatment Is Safe, Tolerable, and Biologically Active for 1 Year in Persons With Amyotrophic Lateral Sclerosis	24
B-Cell Compartmental Features and Molecular Basis for Therapy in Autoimmune Disease	24
Neurological Autoimmunity Associated With Homer-3 Antibody	24
Bickerstaff brainstem encephalitis with or without anti-GQ1b antibody	24
Allogeneic BK Virus-Specific T-Cell Treatment in 2 Patients With Progressive Multifocal Leukoencephalopathy	24
Ofatumumab Modulates Inflammatory T Cell Responses and Migratory Potential in Patients With Multiple Sclerosis	23
Interim Analysis of Pregnancy Outcomes After Exposure to Dimethyl Fumarate in a Prospective International Registry	23
Gut microbiota composition is associated with narcolepsy type 1	23
Impact of Dietary Intervention on Serum Neurofilament Light Chain in Multiple Sclerosis	23
Decrease in Serum Anti-MAG Autoantibodies Is Associated With Therapy Response in Patients With Anti-MAG Neuropathy	23
Neurofilament Light Chain Levels in Multiple Sclerosis Correlate With Lesions Containing Foamy Macrophages and With Acute Axonal Damage	23
Central Vein Sign Profile of Newly Developing Lesions in Multiple Sclerosis	22
Disease activity in pregnancy and postpartum in women with MS who suspended rituximab and natalizumab	22
Human Leukocyte Antigen Association Study Reveals DRB104:02 Effects Additional to DRB107:01 in Anti-LGI1 Encephalitis	22
Baseline Microglial Activation Correlates With Brain Amyloidosis and Longitudinal Cognitive Decline in Alzheimer Disease	22
Safety and Immune Effects of Blocking CD40 Ligand in Multiple Sclerosis	22
Immune Skew of Circulating Follicular Helper T Cells Associates With Myasthenia Gravis Severity	22
Direct economic burden of patients with autoimmune encephalitis in western China	22
CSF Levels of CXCL12 and Osteopontin as Early Markers of Primary Progressive Multiple Sclerosis	22
Predicting Aggressive Multiple Sclerosis With Intrathecal IgM Synthesis Among Patients With a Clinically Isolated Syndrome	22
Longitudinal T-Cell Responses After a Third SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis on Ocrelizumab or Fingolimod	22
Demyelinating Events Following Initiation of Anti-TNFα Therapy in the British Society for Rheumatology Biologics Registry in Rheumatoid Arthritis	22
Guillain-Barré Syndrome Outbreak in Peru 2019 Associated With Campylobacter jejuni Infection	22
Optic Nerve Lesion Length at the Acute Phase of Optic Neuritis Is Predictive of Retinal Neuronal Loss	22
Presence of SARS-CoV-2 Transcripts in the Choroid Plexus of MS and Non-MS Patients With COVID-19	21
Use of Disease-Modifying Therapies in Pediatric Relapsing-Remitting Multiple Sclerosis in the United Kingdom	21
Clinical Features of COVID-19 on Patients With Neuromyelitis Optica Spectrum Disorders	21
Is MS affecting the CNS only?	21
Investigating the Presence of Interattack Astrocyte Damage in Neuromyelitis Optica Spectrum Disorder	21
Anti–Interleukin-6 and Janus Kinase Inhibitors for Severe Neurologic Toxicity of Checkpoint Inhibitors	21
Intrathecal Antibody Production Against Epstein-Barr, Herpes Simplex, and Other Neurotropic Viruses in Autoimmune Encephalitis	20
Kappa Free Light Chain Biomarkers Are Efficient for the Diagnosis of Multiple Sclerosis	20
T-Cell Specificity Influences Disease Heterogeneity in Multiple Sclerosis	20
Mild progressive multifocal leukoencephalopathy after switching from natalizumab to ocrelizumab	20
Anti-CD20 Disrupts Meningeal B-Cell Aggregates in a Model of Secondary Progressive Multiple Sclerosis	20
Mass Cytometry of CSF Identifies an MS-Associated B-cell Population	20
Long-term Efficacy of Satralizumab in AQP4-IgG–Seropositive Neuromyelitis Optica Spectrum Disorder From SAkuraSky and SAkuraStar	20
Evolution of Brain Volume Loss Rates in Early Stages of Multiple Sclerosis	20
CAR-T Cell–Mediated B-Cell Depletion in Central Nervous System Autoimmunity	20
CSF SERPINA3 Levels Are Elevated in Patients With Progressive MS	20
Single-Cell Transcriptomics Identifies Brain Endothelium Inflammatory Networks in Experimental Autoimmune Encephalomyelitis	20
Deep Phenotyping of Neurologic Postacute Sequelae of SARS-CoV-2 Infection	19
Dynamics of Retinal Vessel Loss After Acute Optic Neuritis in Patients With Relapsing Multiple Sclerosis	19
Altered CSF Albumin Quotient Links Peripheral Inflammation and Brain Damage in MS	19
Effect of Estimated Blood Volume and Body Mass Index on GFAP and NfL Levels in the Serum and CSF of Patients With Multiple Sclerosis	19
Argonaute Autoantibodies as Biomarkers in Autoimmune Neurologic Diseases	19
Molecular Level Characterization of Circulating Aquaporin-4 Antibodies in Neuromyelitis Optica Spectrum Disorder	19
Absence of B Cells in Brainstem and White Matter Lesions Associates With Less Severe Disease and Absence of Oligoclonal Bands in MS	19
Autoantibodies Against the Purkinje Cell Protein RGS8 in Paraneoplastic Cerebellar Syndrome	19
Cell-Free DNA Derived From Neutrophils Triggers Type 1 Interferon Signature in Neuromyelitis Optica Spectrum Disorder	19
Multiple Sclerosis	18
Anti-CD20 Depletes Meningeal B Cells but Does Not Halt the Formation of Meningeal Ectopic Lymphoid Tissue	18
Long-term Effectiveness of IVIg Maintenance Therapy in 36 Patients With GAD Antibody–Positive Stiff-Person Syndrome	18
Lymphocyte recovery after fingolimod discontinuation in patients with MS	18
Epigallocatechin Gallate in Relapsing-Remitting Multiple Sclerosis	18
CNS Lymphocytic Vasculitis in a Young Woman With COVID-19 Infection	18
Phenome-wide examination of comorbidity burden and multiple sclerosis disease severity	18

Chitinase 3–like 1 and neurofilament light chain in CSF and CNS atrophy in MS	18
Rituximab-Induced Hypogammaglobulinemia and Risk of Infection in Neuromyelitis Optica Spectrum Disorders	18
COVID-19 in Patients With Neuromyelitis Optica Spectrum Disorders and Myelin Oligodendrocyte Glycoprotein Antibody Disease in North America	18
Paraneoplastic Cerebellar Degeneration	18
Early Reduction of MRI Activity During 6 Months of Treatment With Cladribine Tablets for Highly Active Relapsing Multiple Sclerosis	18
Free light chains kappa can differentiate between myelitis and noninflammatory myelopathy	18
Hemophagocytic Lymphohistiocytosis Gene Mutations in Adult Patients Presenting With CLIPPERS-Like Syndrome	18
Exosomes From Subjects With Multiple Sclerosis Express EBV-Derived Proteins and Activate Monocyte-Derived Macrophages	18
Longitudinal Postvaccine SARS-CoV-2 Immunoglobulin G Titers, Memory B-Cell Responses, and Risk of COVID-19 in Multiple Sclerosis Over 1 Year	18
Analysis of Macrophages and Peptidergic Fibers in the Skin of Patients With Painful Diabetic Polyneuropathy	18
Area Postrema Syndrome in Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy	17
Immune and Genetic Signatures of Breast Carcinomas Triggering Anti-Yo–Associated Paraneoplastic Cerebellar Degeneration	17
Intermediate uveitis associated with MS	17
Perturbed Microbiota/Immune Homeostasis in Multiple Sclerosis	17
Network Damage Predicts Clinical Worsening in Multiple Sclerosis	17
Comparison of Fixed and Live Cell-Based Assay for the Detection of AChR and MuSK Antibodies in Myasthenia Gravis	17
Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple Sclerosis	17
Seizure Semiology in Antibody-Associated Autoimmune Encephalitis	17
Skin Reactions in Patients With Multiple Sclerosis Receiving Cladribine Treatment	17
Aryl Hydrocarbon Receptor Plasma Agonist Activity Correlates With Disease Activity in Progressive MS	17
Placental transfer of NMDAR antibodies causes reversible alterations in mice	17
B Cells in the CNS at Postmortem Are Associated With Worse Outcome and Cell Types in Multiple Sclerosis	17
Novel Cell-Based Assay for Alpha-3 Nicotinic Receptor Antibodies Detects Antibodies Exclusively in Autoimmune Autonomic Ganglionopathy	17
International Delphi Consensus on the Management of AQP4-IgG+ NMOSD	17
Specific Patterns of Immune Cell Dynamics May Explain the Early Onset and Prolonged Efficacy of Cladribine Tablets	16
Genome-wide Association Study Identifies 2 New Loci Associated With Anti-NMDAR Encephalitis	16
Therapies in Stiff-Person Syndrome	16
Mimics of Autoimmune Encephalitis	16
Timing of MOG-IgG Testing Is Key to 2023 MOGAD Diagnostic Criteria	16
Differential Binding of Autoantibodies to MOG Isoforms in Inflammatory Demyelinating Diseases	16
Immune Response and Safety of SARS-CoV-2 mRNA-1273 Vaccine in Patients With Myasthenia Gravis	16
GRP78 Antibodies Are Associated With Blood-Brain Barrier Breakdown in Anti–Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disorder	16
Fatigue in Survivors of Autoimmune Encephalitis	16
Antiplexin D1 Antibodies Relate to Small Fiber Neuropathy and Induce Neuropathic Pain in Animals	15
Interleukin 8, a Biomarker to Differentiate Guillain-Barré Syndrome From CIDP	15
Dimethyl Fumarate Treatment in Patients With Primary Progressive Multiple Sclerosis	15
The BCL2 Inhibitor Venetoclax Plus Rituximab Is Active in MYD88 Wild-Type Polyneuropathy With Anti-MAG Antibodies	15
Allosteric Modulation of NMDARs Reverses Patients' Autoantibody Effects in Mice	15
Vascular Involvement in Neurosarcoidosis	15
Humoral and Cellular Responses to SARS-CoV-2 in Convalescent COVID-19 Patients With Multiple Sclerosis	15
Paraneoplastic Cerebellar Degeneration With P/Q-VGCC vs Yo Autoantibodies	15
Assessing Neurofilaments as Biomarkers of Neuroprotection in Progressive Multiple Sclerosis	15
Mitigating alemtuzumab-associated autoimmunity in MS	15
Interleukin-15 enhances proinflammatory T-cell responses in patients with MS and EAE	14
Epigallocatechin Gallate in Progressive MS	14
MRI activity in MS and completed pregnancy	14
Association of NEDA-4 With No Long-term Disability Progression in Multiple Sclerosis and Comparison With NEDA-3	14
CCR5 Blockade in Inflammatory PML and PML-IRIS Associated With Chronic Inflammatory Diseases' Treatments	14
Neurofilament Light Chain Levels Are Predictive of Clinical Conversion in Radiologically Isolated Syndrome	14
CSF Chitinase 3–Like 2 Is Associated With Long-term Disability Progression in Patients With Progressive Multiple Sclerosis	14
Timing of SARS-CoV-2 Vaccination Matters in People With Multiple Sclerosis on Pulsed Anti-CD20 Treatment	14
Senescent-like Blood Lymphocytes and Disease Progression in Amyotrophic Lateral Sclerosis	14
Increased Intrathecal Activity of Follicular Helper T Cells in Patients With Relapsing-Remitting Multiple Sclerosis	14
Baicalin Promotes CNS Remyelination via PPARγ Signal Pathway	14
Autoimmunity complicating SARS-CoV-2 infection in selective IgA-deficiency	14
CSF-Derived CD4 ⁺ T-Cell Diversity Is Reduced in Patients With Alzheimer Clinical Syndrome	13
Efficacy of Rituximab Outlasts B-Cell Repopulation in Multiple Sclerosis	13
Disease-Modifying Drugs for Multiple Sclerosis and Association With Survival	13
Neuroinflammation-Related Proteins NOD2 and Spp1 Are Abnormally Upregulated in Amyotrophic Lateral Sclerosis	13
CSF neurofilament light chain testing as an aid to determine treatment strategies in MS	13
Cerebellar Ataxia With Anti-DNER Antibodies	13
Cortical and Subcortical Dysmetabolism Are Dynamic Markers of Clinical Disability and Course in Anti-LGI1 Encephalitis	13
Influence of Previous Disease-Modifying Drug Exposure on T-Lymphocyte Dynamic in Patients With Multiple Sclerosis Treated With Ocrelizumab	13
EBNA-1 titer gradient in families with multiple sclerosis indicates a genetic contribution	13
Ocrelizumab Impairs the Phenotype and Function of Memory CD8 ⁺ T Cells	13
Time course of dementia following sepsis in German health claims data	13
CSF Neurofilament Light Chain Concentrations Predict Outcome in Bacterial Meningitis	13
Laminar analysis of the cortical T1/T2-weighted ratio at 7T	12
Innate Immune Cell–Related Pathology in the Thalamus Signals a Risk for Disability Progression in Multiple Sclerosis	12
Targeted RNA Sequencing of VZV-Infected Brain Vascular Adventitial Fibroblasts Indicates That Amyloid May Be Involved in VZV Vasculopathy	12
Interferon-β Is Less Effective Than Other Drugs in Controlling the Rate of Retinal Ganglion Cell Loss in MS	12
TDP-43–specific Autoantibody Decline in Patients With Amyotrophic Lateral Sclerosis	12
Transcription Factor c-Maf Promotes Immunoregulation of Programmed Cell Death 1–Expressed CD8 ⁺ T Cells in Multiple Sclerosis	12
Cryptococcal Meningitis Reported With Fingolimod Treatment	12
Association of Retinal Layer Thickness With Cognition in Patients With Multiple Sclerosis	12
Serum Neurofilament Levels and PML Risk in Patients With Multiple Sclerosis Treated With Natalizumab	12
Antineonatal Fc Receptor Antibody Treatment Ameliorates MOG-IgG–Associated Experimental Autoimmune Encephalomyelitis	12
Siponimod Inhibits the Formation of Meningeal Ectopic Lymphoid Tissue in Experimental Autoimmune Encephalomyelitis	12
Retinal Hyperreflecting Foci Associate With Cortical Pathology in Multiple Sclerosis	12
Brain-homing CD4 ⁺ T cells display glucocorticoid-resistant features in MS	12
Analysis of CSF D-Dimer to Identify Intrathecal Fibrin-Driven Autoimmunity in Patients With Multiple Sclerosis	12
Multiple Sclerosis CSF Is Enriched With Follicular T Cells Displaying a Th1/Eomes Signature	11
Frequency and Referral Patterns of Neural Antibody Studies During the COVID-19 Pandemic	11
Mutational Profile in 75 Patients With Anti–Myelin-Associated Glycoprotein Neuropathy	11
The OSCAR-MP Consensus Criteria for Quality Assessment of Retinal Optical Coherence Tomography Angiography	11
Different Fumaric Acid Esters Elicit Distinct Pharmacologic Responses	11
B-Cell Reconstitution After Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis	11
IgG4 Valency Modulates the Pathogenicity of Anti–Neurofascin-155 IgG4 in Autoimmune Nodopathy	11
Neuroaxonal and Glial Markers in Patients of the Same Age With Multiple Sclerosis	11
More Efficient Complement Activation by Anti–Aquaporin-4 Compared With Anti–Myelin Oligodendrocyte Glycoprotein Antibodies	11
Dramatic Response to Anti-IL-6 Receptor Therapy in Children With Life-Threatening Myelin Oligodendrocyte Glycoprotein-Associated Disease	11
Pachymeningitis in Biopsy-Proven Sarcoidosis	11
Inflammatory Activity After Diverse Fertility Treatments	11
Autoimmune Global Amnesia as Manifestation of AMPAR Encephalitis and Neuropathologic Findings	11
The Aryl Hydrocarbon Receptor–Dependent TGF-α/VEGF-B Ratio Correlates With Disease Subtype and Prognosis in Multiple Sclerosis	11